Kiromic BioPharma, Inc. (KRBP)

Kiromic BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	3.2	0.65	25.35	10.15	1.93
Cash & Cash Equivalents	3.2	0.65	25.35	10.15	1.93
Cash Growth	396.59%	-97.46%	149.78%	426.18%	401.98%
Receivables	0	0	0.02	0	0
Inventory	0	0	0	0	0.02
Other Current Assets	1.23	1.04	1.7	0.59	0.09
Total Current Assets	4.43	1.69	27.07	10.74	2.04
Property, Plant & Equipment	7.72	10.25	3.63	2.07	0.59
Other Long-Term Assets	0.02	0.02	0.03	0.02	0.02
Total Long-Term Assets	7.74	10.28	3.66	2.09	0.61
Total Assets	12.17	11.97	30.73	12.83	2.65
Accounts Payable	2.14	7.31	2.21	0.67	0.45
Deferred Revenue	-14	0	0	0	0
Current Debt	14.63	4.95	0.45	0.47	0
Other Current Liabilities	17.61	1.02	0.74	0.33	0.22
Total Current Liabilities	20.38	13.28	3.41	1.47	0.67
Long-Term Debt	0.91	4.46	0	0	0
Total Long-Term Liabilities	0.91	4.46	0	0	0
Total Liabilities	21.29	17.74	3.41	1.47	0.67
Total Debt	15.54	9.41	0.45	0.47	0
Debt Growth	65.16%	1970.50%	-2.88%	-	-
Common Stock	0	0	0.01	0	0
Retained Earnings	-122.9	-101.95	-67.22	-41.63	-22.43
Comprehensive Income	-0	0	0	0	0
Shareholders' Equity	-9.12	-5.77	27.32	11.36	1.98
Total Liabilities and Equity	12.17	11.97	30.73	12.83	2.65
Net Cash / Debt	-12.34	-8.77	24.9	9.68	1.93
Net Cash / Debt Growth	-	-	157.16%	401.92%	401.98%
Net Cash Per Share	-11.24	-16.10	65.42	64.47	14.92
Working Capital	-15.95	-11.59	23.66	9.27	1.37
Book Value Per Share	-8.31	-10.60	71.78	75.65	15.30

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.